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Abstract.
Background: Souvenaid® (uridine monophosphate, docosahexaenoic acid, eicosapentaenoic acid, choline, phospholipids,
folic acid, vitamins B12, B6, C, and E, and selenium), was developed to support the formation and function of neuronal
membranes.
Objective: To determine effect sizes observed in clinical trials of Souvenaid and to calculate the number needed to treat to
show benefit or harm.
Methods: Data from all three reported randomized controlled trials of Souvenaid in Alzheimer’s disease (AD) dementia
(Souvenir I, Souvenir II, and S-Connect) and an open-label extension study were included in analyses of effect size for
cognitive, functional, and behavioral outcomes. Effect size was determined by calculating Cohen’s d statistic (or Crame´r’s
V method for nominal data), number needed to treat and number needed to harm. Statistical calculations were performed for
the intent-to-treat populations.
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Results: In patients with mild AD, effect sizes were 0.21 (95% confidence intervals: –0.06, 0.49) for the primary outcome in
Souvenir II (neuropsychological test battery memory z-score) and 0.20 (0.10, 0.34) for the co-primary outcome of Souvenir
I (Wechsler memory scale delayed recall). No effect was shown on cognition in patients with mild-to-moderate AD (S-
Connect). The number needed to treat (6 and 21 for Souvenir I and II, respectively) and high number needed to harm values
indicate a favorable harm:benefit ratio for Souvenaid versus control in patients with mild AD.
Conclusions: The favorable safety profile and impact on outcome measures converge to corroborate the putative mode of
action and demonstrate that Souvenaid can achieve clinically detectable effects in patients with early AD.
Keywords: Alzheimer’s disease, effect size, number-needed-to-treat, Souvenaid
INTRODUCTION
Cognitive decline, particularly episodic memory
loss, is one of the first symptoms of Alzheimer’s
disease (AD). As AD progresses, cognitive decline
leads to impairments in functional abilities. Mem-
ory impairment is associated with increasing synaptic
abnormalities [1], and synaptic dysfunction is now
recognized as one of the pathological hallmarks of
AD [2]. Slowing or even reversing synaptic dys-
function offers a potential approach to modify the
inexorable progression of AD. Data showing that
the availability of specific nutrients influences the
structure and functionality of neuronal membranes
provided a scientific rationale for investigating nutri-
tional interventions to support synaptic function [3].
Furthermore, studies have shown that patients with
early AD have a poorer nutrient status despite a
putative increase in their nutritional need to support
the formation of neuronal membrane components
[4]. Accumulating evidence from clinical and epi-
demiological studies showing that nutritional factors
can influence AD risk and progression has encour-
aged the implementation of dietary and lifestyle
guidelines to help adults reduce their risk [5]. AD pro-
gression involves multiple factors interacting over a
long period of time, suggesting the need for multi-
modal lifestyle approaches with the potential to
influence many biological processes that contribute
to neurological decline. The concept of using dietary
modification and nutritional support to provide neu-
roprotection is compelling [5].
Souvenaid is a food for special medical pur-
poses that contains the nutrient combination Fortasyn
Connect (docosahexaenoic acid 1200 mg, eicosapen-
taenoic acid 300 mg, uridine monophosphate 625 mg,
choline 400 mg, folic acid 400 mcg, vitamin B6 1 mg,
vitamin B12 3 mcg, vitamin C 80 mg, vitamin E
40 mg, selenium 60 mcg, and phospholipids 106 mg).
These precursors and cofactors are necessary to form
neuronal membranes and hypothesized to support
the synthesis of new synapses and maintenance of
existing synapses [6]. Preclinical studies demon-
strated that Fortasyn Connect increases markers of
synaptogenesis [3, 7, 8], enhances neurotransmitter
synthesis and release [8], preserves white and grey
matter integrity [9], improves cerebral blood flow and
volume [9], reduces amyloid- production and tox-
icity [10, 11], and restores neurogenesis [12], all of
which may contribute to an overall neuroprotective
effect.
Three double-blind, multi-center, randomized,
controlled clinical trials (RCTs) evaluated the effects
of Souvenaid on cognition and memory perfor-
mance in patients with AD [13–16]. The trials used
clinically relevant, validated tests of cognitive and
memory performance. Since memory performance
directly correlates with quantitative and qualitative
measures of synapse function [1, 2], such standard
tests might also serve as a proxy measure of synapto-
genesis and neuroprotection. Results from Souvenir
I (12-week duration) [13] and Souvenir II (24-
week duration) [14] showed that Souvenaid improved
memory performance in patients with mild AD not
taking AD medication (Mini-Mental State Examina-
tion [MMSE] 20–26 and MMSE ≥20, respectively).
In Souvenir I, the co-primary outcome measures
were the 12-week change from baseline on the
delayed verbal recall test of the Wechsler Mem-
ory Scale revised edition (WMS-r) and the 13-item
modified Alzheimer’s Disease Assessment Scale-
cognitive subscale (ADAS-cog). Souvenaid signifi-
cantly improved the co-primary endpoint of WMS-r
delayed verbal recall after 12 weeks of intervention
versus control. However, no effect was observed on
the other co-primary outcome (ADAS-cog) [13]. In
Souvenir II, the primary outcome parameter was the
memory domain composite z-score based on a Neu-
ropsychological Test Battery (NTB). This memory
composite score was derived from the Rey Audi-
tory Verbal Learning Test (RAVLT: immediate recall,
delayed recall, and recognition performance) and the
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WMS-r verbal paired associates (VPA) immediate
and delayed recall. Significant improvements were
observed on the NTB memory domain z-score for
the active versus control group during the 24-week
study period (p = 0.023). In addition, an exploratory
analysis of results from a 24-week open-label exten-
sion (OLE) of Souvenir II suggested that memory
function improved throughout 48 weeks in patients
with mild AD taking Souvenaid [16]. The third RCT
in patients with more advanced dementia (mild-to-
moderate AD; MMSE 14–24) and receiving AD
medication did not show an effect of Souvenaid on
cognition [15].
While Souvenaid achieved statistically significant
improvements in the primary outcome measures of
memory performance in patients with mild AD,
assessing the magnitude of these effects in the context
of progressively deteriorating cognitive performance
is challenging. Effect size analysis, which indicates
the size or magnitude of the difference between the
groups, is regarded as a useful tool in the assessment
of clinical interventions [17]. Accepted measures
of effect size include the mean difference between
groups (Cohen’s d), where effect sizes are conven-
tionally defined as small (d = 0.20, medium (d = 0.50)
and large d = 0.80) [18], and Crame´r’s V, which is
usually interpreted in the same way as Cohen’s d
[19]. In evidence-based medicine, analyses of num-
ber needed to treat (NNT) and number needed to harm
(NNH) are the preferred indices for the effect of an
intervention [20]. NNT data estimate the number of
individuals that need to be treated with the interven-
tion of interest for one person to benefit compared
with a control subject in a clinical study. NNH data
estimate the number of individuals that are treated
for one person to experience an adverse outcome
compared with a control subject in a clinical study.
Effect size analyses have been reported previously
for drug therapies in patients with AD [17], but,
to our knowledge, not for nutritional approaches.
Effect size quantification and NNT/NNH analysis
may be informative in the assessment of nutritional
interventions for AD in the context of the overall man-
agement of these patients and relevance for clinical
practice.
To determine the magnitude of the effect of Sou-
venaid observed in clinical trials of patients with
AD, effect size indices and NNT and NNH values
were calculated for the three completed RCTs and the
OLE study. Here we present results from effect size
and NNT/NNH analyses for cognitive, functional and
behavioral outcomes, as well as safety parameters.
MATERIALS AND METHODS
Study populations
The study population comprised all patients for
whom Souvenaid data are available including data
from Souvenir I, Souvenir II, or S-Connect studies
performed between 2006 and 2011. The study pop-
ulation and methodology of the studies have been
described in detail previously [13–16]. Briefly, all
studies included men and women ≥50 years of age
who were diagnosed with probable AD according to
the National Institute of Neurological and Commu-
nicative Disorders and Stroke-Alzheimer’s Disease
and Related Disorders Association criteria [21]. Eli-
gible patients had mild AD, defined by an MMSE
score of 20–26 inclusive (Souvenir I) or ≥20 (Sou-
venir II), or mild-to-moderate AD, defined by an
MMSE score of 14–24 inclusive (S-Connect). Sub-
jects in Souvenir I and II had to be drug-free for AD
medication, whereas subjects in S-Connect had to be
on a stable dose of approved AD medication. In addi-
tion, a 24-week OLE study to the Souvenir II study
was performed between 2010 and 2012 to evaluate
longer-term safety and compliance with Souvenaid
(i.e., total intervention period of 48 weeks). Eligibil-
ity criteria for the OLE study allowed patients to use
AD medication. All subjects received Souvenaid or a
control product (similar across studies) once-daily for
the duration of the study. All trials were registered in
the Dutch Trial Register (Souvenir I: NTR702, Sou-
venir II: NTR1975, S-Connect: NTR1683 and OLE:
NTR2571). The institutional review boards of each
participating centers approved the studies. Written
informed consent was obtained from all study partic-
ipants and study partners prior to conducting study
procedures.
Outcome measures
Effect sizes and NNT were calculated for all
cognitive, functional, and behavioral outcome param-
eters. In Souvenir I, changes from baseline were
measured at week 12 for the following endpoints:
WMS-r immediate and delayed verbal recall, modi-
fied 13-item cognitive subscale of the ADAS-Cog-13,
MMSE, Alzheimer’s Disease Cooperative Study –
Activities of Daily Living Inventory (ADCS-ADL),
Neuropsychiatry Inventory (NPI), Clinician’s Inter-
view Based Impression of Change plus Caregiver
Input (CIBIC-plus) (at week 12), and Quality of Life
in Alzheimer’s Disease (QOL-AD) composite score.
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Table 1
Number needed to treat for Souvenaid compared with control in three randomized controlled clinical trials
and an open-label extension (OLE) study
Event Rate (%)
Study Outcome Parameter Active Control NNT∗
Souvenir I (12 weeks) ADAS-cog-13: < –4 17.8 11.1 15
WMS-r delayed memory: >0 40.0 24.5 6
WMS-r immediate memory: >0 50.0 39.8 10
MMSE: >0 45.9 41.1 21
Souvenir II NTB memory: ≥0.0 68.9 64.1 21
(24 weeks) NTB memory: ≥0.3 37.9 26.2 9
NTB executive function: ≥0.3 24.7 16.2 12
NTB total score: ≥0.0 63.9 53.9 10
NTB total score: ≥0.3 25.3 14.6 9
OLE† NTB memory: ≥0.0 73.6 57.8 6
(48 weeks) NTB memory: ≥0.3 51.3 34.3 6
S-Connect (24 weeks) ADCS-ADL: >0 31.1 23.8 14
∗The number needed to treat (NNT) data give an estimation of the number of individuals that need to be treated
with the active product (Souvenaid) for one to benefit compared with the control product. Positive values are
indicative of a better response to active versus control and vice versa. The lower the NNT, the more effective
the treatment (ideal NNT = 1). High values are indicative of small differences between groups (i.e., no effective
treatment). Cut-off values for the occurrence of an ‘event’ (yes/no) were calculated as the change from baseline
at study endpoint, except for CIBIC-plus (values at week 12 were used). †Calculations based on data method (see
paragraph Statistical Analyses).
In Souvenir II, changes from baseline were measured
at week 24 for the following endpoints: NTB mem-
ory domain z-score, NTB executive function domain
z-score, NTB total composite z-score, and Disabil-
ity Assessment in Dementia (DAD) scale. In the OLE
of Souvenir II, changes from baseline were measured
at week 48 for the NTB memory domain z-score. In
S-Connect, changes from baseline were measured at
week 24 for the following endpoints: ADAS-Cog-11,
acognitivecompositez-scorebasedonfourneuropsy-
chological tests (Digit Span from the WMS – Third
Edition], the Concept Shifting Test, the Letter Digit
Substitution Test, and Category Fluency), ADCS-
ADL, and Clinical Dementia Rating – Sum of Boxes
(CDR-SB). Standardized effect sizes for the primary
endpoints assumed in the study protocols were 0.45
(ADAS-cog-13) and 0.47 (WMS-r delayed) for Sou-
venir I, 0.40 (Memory domain z-score) for Souvenir
II, and 0.19 (ADAS-cog-11) for S-Connect.
NNH was calculated for reported adverse events
(AEs), i.e., any AE, related AEs and AEs in spe-
cific body systems (body as a whole, gastrointestinal
system disorders, central and peripheral nervous sys-
tem disorders, psychiatric disorders, and respiratory
system) and the drop-out rate.
Statistical analyses
Effect sizes for continuous parameters with a nor-
mal distribution were calculated using the mean
change from baseline in both the active (Souvenaid)
and control groups and the pooled standard devia-
tion of the change from baseline in both groups using
the Cohen’s d statistic [18]. The Crame´r’s V method
was used to calculate effect sizes for nominal data
[19]. Cohen’s d values range from –∞ to +∞, and
are presented so that a positive effect size indicates
improvement in the active (Souvenaid) group versus
control and vice versa. Crame´r’s V values range from
0 (no association) to 1 (perfect association).
NNT and NNH were calculated as ‘100/(event rate
in active group [%] – event rate in control group [%])’
and rounded up to the nearest number. Literature and
current trial results were used to define cut-off values
for the occurrence of an ‘event’ (yes/no) (Table 1).
Unless the effect size was significantly different from
zero, a negative NNT or NNH was not reported. For
a significant effect size, a negative NNT was reported
as a NNH for the given outcome, and a negative NNH
was reported as a NNT.
For the OLE study, effect size and NNT for the
NTB memory domain z-score could not be calculated
directly because there was no control group. There-
fore, the change in NTB memory domain z-score
during the OLE study was estimated for a control
group using two different extrapolation methods con-
verted to a 24-week period: (1) the change from
week 12 measured at week 24 in the control group
of Souvenir II (data method), and (2) the change
from baseline in a memory composite from the AN-
1792 active vaccination trial [22] measured at month
12 (literature method). NNH for the OLE study was
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Fig. 1. Effect sizes (point estimate and 95% CI) for the main primary and secondary outcome measures in the Souvenir I (•), Souvenir II
(), open-label extension (OLE) (), and S-Connect () studies in patients with mild and mild to moderate Alzheimer’s disease. Mean
baseline values of the Mini-Mental State Examination (MMSE) score of the total study populations are shown in the figure. Effect sizes were
calculated using Cohen’s d [18] (red) for change from baseline values, except for CIBIC-plus (values at week 12 were used), and Crame´r’s
V [19] (blue) for nominal data. Cohen’s d values range from –∞ to +∞, with a positive effect size indicating improvement in the active
(Souvenaid) group versus control and vice versa. Crame´r’s V values range from 0 (no association) to 1 (perfect association).
calculated based on the occurrence of AEs in the con-
trol group of the Souvenir II study period and the
occurrence of new AEs in all subjects during the OLE
period.
Calculations were performed for the ITT popu-
lations of the studies. Data are presented as point
estimates and 95% confidence intervals (CI) unless
stated otherwise. Statistical analyses were performed
using SAS® software (SAS Enterprise Guide 4.3 for
Windows, SAS Institute Inc., Cary, NC, USA). The
statistical analyses were performed and validated by
an independent statistician not involved with the orig-
inal clinical trial data analyses.
RESULTS
The effect sizes and NNT values for the three RCTs
and the OLE study are shown in Fig. 1 and Table 1,
respectively. Table 1 does not show data for outcome
parameters where the NNT values were negative or
greater than 25 because these data are not considered
to be statistically meaningful. Specifically, NNT data
for the following endpoints were not considered to
be meaningful in the context of this analysis: ADCS-
ADL: >0 and QOL-AD: >0 for Souvenir I; DAD:
≥ 0 for Souvenir II; ADAS-cog-11: < –4, Cognitive
composite: ≥0.0 and CDR-SB: <0 for S-Connect) or
greater than 25 (ADAS-cog-13: <–7, NPI: <0, and
CIBIC-plus: ≤3 for Souvenir I; NTB executive func-
tion: ≥0.0 for Souvenir II; ADAS-cog-11: <–7 and
Cognitive composite: ≥0.3 for S-Connect).
In Souvenir I, the co-primary outcome measures
were the 12-week change from baseline on the
delayed verbal recall test of the WMS-r and the
13-item modified ADAS-cog. The Cohen’s d effect
size for WMS-r delayed recall was 0.20 (95% confi-
dence intervals [CI] 0.10, 0.34). The 95% CIs for the
Crame´r’s V effect size of the co-primary outcome
WMS-r delayed recall in Souvenir I were 0.10 to
0.34. No detectable effect was seen on the 13-item
modified ADAS-cog. Calculated NNT values were 6
for WMS-r delayed recall and 15–26 for ADAS-cog
(Table 1). NNH values in the Souvenir I study ranged
from 13 (any AE) to 138 (AEs related to gastrointesti-
nal disorders). The NNH value for study drop-out in
Souvenir I was 58.
In Souvenir II, the Cohen’s d effect size for the
primary outcome (NTB memory z-score) was 0.21
(–0.06, 0.49). The 95% CIs for the Cohen’s d effect
size of NTB total z-score (Souvenir II) were greater
than zero (0.002, 0.604). NNT values for the NTB
memory score ranged from 9 to 21. For the Souvenir
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II and OLE studies, event rates for all type of AEs
were lower in the Souvenaid group than the control
group, therefore NNH were not applicable. The NNH
values for study drop-out were 65 and 206 in Souvenir
II and the OLE, respectively.
For the two RCTs in mild AD (Souvenir I and
Souvenir II), the effect sizes for 11 of the 13 cogni-
tion/memory, function and behavior measures were
positive, ranging from a point estimate of 0.06 (95%
CI 0.00, 0.19) to 0.30 (0.00, 0.60). In two of the
13 measures, (QOL-AD –0.15 [–0.43, 0.13] and
the DAD score –0.16 [–0.42, 0.09]) the 95% con-
fidence intervals crossed zero (Fig. 1). Analyses of
the exploratory efficacy parameter in the OLE study,
the NTB memory z-score, showed effect sizes of 0.45
(0.14, 0.75) and 0.53 (0.22, 0.84), and NNT values of
6 and 5 using the data method (Fig. 1, Table 1) and
the literature method, respectively.
In S-Connect, in patients with mild-to-moderate
AD, the primary outcome of cognition was assessed
by the 11-item ADAS-cog. The effect sizes for cog-
nition and function were negative and close to zero,
ranging from –0.11 (–0.32, 0.10) to –0.01 (–0.19,
0.18). Corresponding NNT values were high or could
not be calculated (Table 1), except for ADCS-ADL
(NNT = 14). Together, these data suggest no signifi-
cant benefit on the assessed cognitive and functional
outcomes for Souvenaid versus control during 24
weeks in patients with mild-to-moderate AD taking
AD medication. NNH values in the S-Connect study
ranged from 36 to 109 for AEs related to respiratory
disorders and gastrointestinal disorders, respectively,
or were not calculable.
DISCUSSION
This analysis assessed the effect sizes of Souve-
naid in patients with mild AD or mild-moderate AD.
Analysis of the Souvenir II trial in patients with mild
AD showed that the effect size for the primary end-
point (NTB memory) was ≥0.20. Similarly, in the
Souvenir I study, the effect size for the co-primary
endpoint (WMSr delayed recall) is considered large
enough to be detectable. NNT values for the NTB
total score, ADAS-cog and memory outcomes in Sou-
venir I and Souvenir II ranged from 6 to 26 on one
overall cognitive outcome (NTB total score) and the
specific memory outcomes at 12 to 24 weeks. For the
two memory outcome measures the effect sizes were
smaller than the protocol assumptions, but reached
statistical significance. The difference between actual
effect sizes and protocol assumptions is attributable
to a conservative estimation in the variance and more
powerful tests used in the analysis of results com-
pared with the power calculation used in the trial
protocols.
Memory performance represents a clinically rel-
evant outcome measure because impairment in this
domain is typically the earliest and most pervasive
symptom in AD. Furthermore, memory preservation
may be considered as a proxy for neuroprotective
effects of an intervention in early AD that achieves
beneficial effects on disease-relevant pathological
processes. A significant association has been demon-
strated between memory impairment and loss of
synapses [1]. In S-Connect, conducted in patients
with mild-moderate AD taking AD medication,
effects were not detectable. The ADAS-cog used as
the primary outcome of the S-Connect study was
less sensitive to cognitive effects than the WMSr in
the Souvenir I study and this may have contributed
to the absence of a detectable benefit in S-Connect.
Biologically, the production of synapses is compro-
mised by reduced neuronal number and the potential
to benefit from neuroprotection and synaptogenesis
may be limited in later stages of AD-related demen-
tia (i.e., mild-moderate) compared with (very) mild
AD-related dementia because of the more marked
neurodegeneration.
The primary efficacy endpoint in Souvenir II was
the NTB memory domain score, a composite mea-
sure of individual memory test scores [23]. Compared
with a single memory item, the NTB memory domain
score has the advantage of clustering raw memory
test scores, which decreases variation associated with
individual tests and helps to improve the strength of
the underlying cognitive constructs [14]. The NTB
total score comprises all NTB components includ-
ing tests of memory and executive functioning. In the
primary analysis of Souvenir II, Souvenaid demon-
strated a significant effect on NTB memory score
(the primary endpoint) and there was a trend for an
effect on NTB total score (a secondary endpoint) over
the 24-week study period [14]. The present analy-
sis suggests a more pronounced effect size for NTB
total than for NTB memory. However, these effect
size analyses are based on change from baseline at
week 24, whereas p-values for NTB scores in the
primary analysis of Souvenir II are based on the tra-
jectory of the scores over the 24-week time period
[14]. Analysis of the OLE showed that in patients
treated for 48 weeks, the effect size for NTB memory
was more pronounced than observed at 24 weeks
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in Souvenir II. Effect size and NNT values in the
OLE are based on assumptions because there was no
control group in this open-label study setting. This
is an important limitation for the interpretation of
these results and should be taken into consideration
when assessing this study in the context of the wider
literature.
Effect size, NNT and NNH analyses help to inform
discussion about whether interventional effects may
be considered clinically meaningful by identifying
where the benefit is likely to occur, by indicating how
likely the benefit is to be observable and by providing
an overall assessment of the risk:benefit ratio [17].
Effect sizes previously reported for cholinesterase
inhibitors were 0.15, 0.23, and 0.28 for low, medium,
and high doses, respectively, based on the primary
endpoint of ADAS-Cog [17]. NNT values reported
for anti-dementia drugs ranged from 4–14, using cog-
nition as a clinical endpoint, whereas NNH values
ranged from 6–20 [24–26]. The magnitude of these
effect sizes was considered sufficient for regulatory
approval and clinical use [27].
Evidence shows that levels of specific nutrients
needed to support the formation of phospholipids
and to maintain neuronal membrane integrity may
be reduced in patients with AD [4]. Clinical trials
in patients with early AD showed that Souvenaid
increases the availability of these nutrients [28] and
improves memory performance [13, 14, 16]. NNT
values of 6–10/21 (for memory) suggest that for
every six patients taking Souvenaid one will achieve
a clinically detectable benefit in memory perfor-
mance. However, NNT calculations are valid only
when the outcome measure in question, for example
WMS-r delayed memory in Souvenir I, is statisti-
cally different between interventions. NNH values for
Souvenaid are very high or not calculable, in accor-
dance with its good safety and tolerability profile. In
the three RCTs, there were no significant differences
in the incidence of adverse events between Souve-
naid and control groups [13–15]. Overall, the NNT
and NNH values indicate a favorable harm:benefit
ratio for Souvenaid versus control in patients with
mild AD, and inconclusive findings in patients with
moderate AD. The favorable harm:benefit ratio and
impact on disease-relevant outcome measures (effect
size) converge to corroborate the benefit of the
intervention.
The limitations of these analyses are the relatively
small sample sizes and a limited duration of follow up
in the controlled studies included. Placebo or practice
effect observed after 12 weeks (the first assessments
after baseline) for the overall NTB memory domain
and various other NTB parameters in Souvenir II
make it impossible to compare data from Souvenir
I and II studies at similar time points. Although
the OLE study period provides follow up through
48 weeks, this part of study does not have a con-
trol arm and projections are used to calculate effect
sizes. Measurements of changes in cognitive tests are
subject to potential methodological variation, which
may impact the interpretation of NNT values deter-
mined from multiple endpoints. The primary and
secondary endpoints were not identical between dif-
ferent studies and, therefore, we have reported NNT
values for all main outcome measures. In line with
the primary analyses, benefits were not shown in
other domains, such as behavior and function, which
may be attributable to the early stage of disease of
the participants and lack of sensitivity of the out-
come measures used. In addition, the trial populations
included in the analyses are not identical. In the
S-Connect trial, all patients were being treated with
an acetylcholinesterase inhibitor, memantine, or both,
and the mean MMSE in the active group was 19.5,
whereas in both Souvenir I and Souvenir II trials,
concurrent drug therapy for AD was not permitted
and mean MMSE scores were higher (23.8 and 24.9,
respectively), reflecting a less severe disease stage at
study entry. All RCTs conducted with Souvenaid in
AD dementia have been published and there is no
publication bias for the available data.
The effect of Souvenaid on memory performance
in patients with early AD should be evaluated in the
context of the worsening AD trajectory. Addition-
ally, the possibility of idiosyncratic effects should
be considered. For example, individuals with cogni-
tively demanding roles who perform well on standard
measures and indicate high levels of cognitive per-
formance, may also report difficulties successfully
carrying out their jobs. These patients may have
experienced relatively small, but crucial, levels of
cognitive decline. A nutritional approach that can
reverse even modest levels of memory impair-
ment without safety risks may be a useful option
for such individuals as part of an overall clini-
cal management approach for patients with early
AD. Combining nutritional management specifically
designed for neuroprotection with other lifestyle
interventions such as cognitive stimulation and phys-
ical exercise may contribute to an enhanced effect
size. Indeed, in this complex multifactorial disease,
several small steps may be critical to meaningful
progress.
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